Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06947928 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Or Metastatic Merkel Cell Carcinoma

Interventions

DRUG: IFx-Hu2.0
DRUG: Placebo
DRUG: Pembrolizumab

Sponsor

TuHURA Biosciences, Inc.